Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) and Modulight Corporation announced FDA approval for the ML6710i photodynamic laser. This laser is approved for use with Bausch + Lomb's VISUDYNE® therapy, targeting predominantly classic subfoveal choroidal neovascularization caused by Age-related Macular Degeneration (AMD). The ML6710i, designed for easy use and transport, will be available in the first half of 2023. This innovation addresses a significant unmet need in photodynamic therapy, allowing eye care professionals to treat patients more effectively.
Bausch + Lomb Corporation (BLCO) will announce its fourth-quarter and full-year 2022 financial results on February 22, 2023. The company will hold a conference call at 8:00 a.m. ET to discuss the financial outcomes and provide an update on business developments. Interested parties can access the call via web link or dial-in options for both North American and international participants. Replay details will also be available until March 8, 2023.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has acquired AcuFocus, a leader in ophthalmic medical devices, enhancing its surgical portfolio with the IC-8 Apthera intraocular lens (IOL). This IOL, approved by the FDA in July 2022, is the first small aperture non-toric EDOF IOL, catering to cataract patients with up to 1.5 diopters of astigmatism. The global premium cataract IOL market is projected to grow at a CAGR of approximately 13% from 2022 to 2027. With 94 million people affected by cataracts worldwide, Bausch + Lomb aims to offer innovative solutions to meet unmet medical needs, driving long-term growth.
Bausch + Lomb Corporation (BLCO) has introduced PreserVision® AREDS 2 Formula mini soft gels with the new OCUSorb™ technology, enhancing the absorption of lutein and zeaxanthin. This product maintains the clinically proven AREDS 2 formula, which is vital for individuals with Age-related Macular Degeneration (AMD), a leading cause of vision loss in older adults. The new formulation offers superior nutrient absorption, aiming to support the nearly 16 million Americans affected by AMD. It is now available nationwide in retail outlets and online.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health leader, will present a company update at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:00 p.m. PT. This presentation will highlight recent performance, achievements, and future goals for the company. The presentation can be accessed on their Investor Relations page. With over 400 products, Bausch + Lomb is committed to enhancing vision for individuals worldwide, supported by a robust global presence.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:00 p.m. PT. CEO Joseph C. Papa and CFO Sam Eldessouky will represent the company, which focuses on eye health products. A live webcast will be available on the company’s Investor Relations page. Founded in 1853, Bausch + Lomb offers over 400 products, including contact lenses and ophthalmic surgical devices, serving customers in nearly 100 countries.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) and Novaliq GmbH are advancing NOV03, a new ophthalmic solution targeting dry eye disease linked to Meibomian gland dysfunction. Recent publication in Ophthalmology highlights positive results from the pivotal Phase 3 GOBI trial, meeting all co-primary endpoints with statistical significance achieved as early as day 15. The FDA has set a PDUFA date of June 28, 2023 for NOV03's review, which could provide a much-needed treatment option for millions suffering from this condition.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched the ‘Screen, Protect, Cure’ campaign to raise awareness about glaucoma during Glaucoma Awareness Month. This initiative aims to educate at-risk individuals on the importance of early detection and treatment. The campaign features a fundraising challenge matching up to $20,000 for glaucoma research. Currently, about three million people in the U.S. are affected by this sight-threatening disease, highlighting the need for continued education and research in eye health.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced that CEO Joseph C. Papa will continue in his role until at least March 4, 2023, per an Amended Separation Agreement. The agreement allows for potential extensions until June 30, 2023, depending on the Board's discretion or the appointment of a successor. Changes to Papa's compensation were also noted. Bausch + Lomb is a global eye health leader with a portfolio exceeding 400 products, and it operates in nearly 100 countries. For more information, visit www.bausch.com.
Bausch + Lomb (NYSE: BLCO) has received FDA 510(k) clearance for its Biotrue Hydration Boost Contact Lens Rehydrating drops. This preservative-free product is designed for soft and rigid gas permeable lenses, providing up to eight hours of moisture. With one-third of the 45 million U.S. contact lens wearers experiencing dryness, this product is expected to cater to a significant market need. The drops contain hyaluronan and match the pH of healthy tears, enhancing user comfort. Availability is anticipated in the first half of 2023.